Welcome to our dedicated page for McKesson SEC filings (Ticker: MCK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
McKesson Corporation filings document operating results, capital structure, financing arrangements, governance matters, and registered securities for the healthcare services and pharmaceutical distribution company. Its 8-K reports include quarterly and annual results, financial guidance, share repurchase authorizations, dividend-related disclosures, and Regulation FD materials connected to earnings communications.
McKesson's SEC records also cover material credit agreements, including revolving credit facilities and subsidiary senior secured facilities, as well as executive officer transition disclosures and related arrangements. The filing record identifies NYSE-listed common stock and debt securities, including notes due 2026 and 2029, and includes a Form 25 notice for removal from listing and registration of notes due 2025.
McKesson Corporation (MCK) filed a Current Report on Form 8-K dated August 6, 2025. The Company states it furnished its preliminary results for the quarter ended June 30, 2025, which are attached as Exhibit 99.1 (earnings release). The filing clarifies that the information, including Exhibit 99.1, is furnished to the SEC and shall not be deemed "filed" under Section 18 of the Exchange Act or incorporated by reference except by specific reference.
Key filing details:
- Report date: August 6, 2025
- Exhibits filed: 99.1 (earnings release) and 104 (iXBRL cover page)
- Signed by: Britt J. Vitalone, Executive Vice President and Chief Financial Officer
- Securities listed on NYSE: Common stock (MCK), 1.500% Notes due 2025 (MCK25), 1.625% Notes due 2026 (MCK26), 3.125% Notes due 2029 (MCK29)
McKesson Corporation (NYSE: MCK) filed an 8-K summarizing the 30 July 2025 Annual Meeting results (Item 5.07).
- All 12 director nominees were re-elected; support exceeded 95% of votes cast, with only ~0.9-4.7 m "against" votes and 10.3 m broker non-votes per nominee.
- Shareholders ratified Deloitte & Touche LLP as independent auditor for FY 2026 by a 92% majority (102.2 m for / 8.6 m against / 0.1 m abstain).
- The advisory say-on-pay proposal also passed with ~92% approval (91.8 m for / 8.0 m against / 0.8 m abstain).
No additional business, strategic announcements or financial guidance were disclosed. The outcome signals continued investor confidence in board composition, executive pay and audit oversight but carries limited immediate valuation impact.